Tolerance and Oncological Outcomes of In-Field Reirradiation for Locally Recurrent Breast Cancer: A Long-Term Single-Center Experience.
breast cancer
efficacy
radiation therapy
recurrence
reirradiation
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
11
08
2023
revised:
04
09
2023
accepted:
07
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
The management of cancer relapse in previously irradiated tissues is a challenging therapeutic issue. The aim of this work was to report our experience with breast reirradiation for locoregionally recurrent breast cancer. All patients who underwent breast or chest wall in-field reirradiation at the Institut Curie, Paris, France, between 2003 and 2019, were identified. Efficacy outcomes and physician-reported toxicities were retrospectively assessed. A total of 21,372 patients underwent breast irradiation in our institution. Of these, 28 received a second course of radiotherapy to the homolateral breast/chest wall. A total of 18 (64%) patients were treated with a curative intent, and 10 (36%) were treated for palliative purposes. Only one acute and one late grade 3 adverse events were reported. One patient with major cardiovascular risk factors died of myocardial infarction 13 months after left breast reirradiation. The 2-year LRFS, OS, DSS, PFS and MFS were 59%, 79%, 82%, 46% and 75%, respectively, in the whole cohort. The 2-year LRFS (72% vs. 31%, Breast/chest wall reirradiation appears to be feasible with good disease control, especially in patients treated with a curative intent, and presents acceptable toxicity rates.
Sections du résumé
BACKGROUND
BACKGROUND
The management of cancer relapse in previously irradiated tissues is a challenging therapeutic issue. The aim of this work was to report our experience with breast reirradiation for locoregionally recurrent breast cancer.
METHODS
METHODS
All patients who underwent breast or chest wall in-field reirradiation at the Institut Curie, Paris, France, between 2003 and 2019, were identified. Efficacy outcomes and physician-reported toxicities were retrospectively assessed.
RESULTS
RESULTS
A total of 21,372 patients underwent breast irradiation in our institution. Of these, 28 received a second course of radiotherapy to the homolateral breast/chest wall. A total of 18 (64%) patients were treated with a curative intent, and 10 (36%) were treated for palliative purposes. Only one acute and one late grade 3 adverse events were reported. One patient with major cardiovascular risk factors died of myocardial infarction 13 months after left breast reirradiation. The 2-year LRFS, OS, DSS, PFS and MFS were 59%, 79%, 82%, 46% and 75%, respectively, in the whole cohort. The 2-year LRFS (72% vs. 31%,
CONCLUSION
CONCLUSIONS
Breast/chest wall reirradiation appears to be feasible with good disease control, especially in patients treated with a curative intent, and presents acceptable toxicity rates.
Identifiants
pubmed: 37760484
pii: cancers15184515
doi: 10.3390/cancers15184515
pmc: PMC10527329
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Radiother Oncol. 2021 Dec;165:142-151
pubmed: 34688807
Breast Cancer Res Treat. 2019 Jul;176(1):149-157
pubmed: 30949798
Strahlenther Onkol. 2018 Sep;194(9):806-814
pubmed: 29796694
Radiother Oncol. 1997 Jan;42(1):25-9
pubmed: 9132822
Breast Cancer Res Treat. 2021 Jul;188(2):409-414
pubmed: 33770311
JAMA Oncol. 2020 Jan 01;6(1):75-82
pubmed: 31750868
Clin Transl Oncol. 2023 Jul 29;:
pubmed: 37515701
Clin Transl Radiat Oncol. 2022 Nov 01;38:71-76
pubmed: 36388247
Int J Radiat Oncol Biol Phys. 2023 Jul 15;:
pubmed: 37459998
Breast J. 2019 Nov;25(6):1160-1170
pubmed: 31338974
Acta Oncol. 2022 Apr;61(4):441-448
pubmed: 35139725
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
Cancer Radiother. 2021 Jun;25(4):358-365
pubmed: 33676830
Radiother Oncol. 2015 Nov;117(2):223-8
pubmed: 26542015
Cancer Radiother. 2020 Oct;24(6-7):576-585
pubmed: 32830054
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):687-91
pubmed: 12062613
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1073-87
pubmed: 26899950
Radiother Oncol. 2014 Mar;110(3):477-81
pubmed: 24342456
Radiother Oncol. 2013 Nov;109(2):188-93
pubmed: 23742962
Adv Radiat Oncol. 2020 Dec 17;6(1):100640
pubmed: 33506143
Adv Radiat Oncol. 2021 May 09;6(4):100710
pubmed: 34409209
Curr Oncol. 2023 Jan 13;30(1):1151-1163
pubmed: 36661737